HD-OPM Archive
Topics › GLP-1 drugs (semaglutide, tirzepatide)

Oral semaglutide did not slow Alzheimer's progression in EVOKE phase 3 trials

Louis Nervegna · Nov 30, 2025 · ♥ 4 reactions · 2 comments · original Facebook post
GLP-1 drugs (semaglutide, tirzepatide)Brain health & dementia
AI summary & key facts

MedPage Today reports that Novo Nordisk announced the EVOKE phase III trials of oral semaglutide found no slowing of Alzheimer's disease progression. The post is a brief news share.

#glp1HD #alzheimersHD

Research cited

The oral GLP-1 receptor agonist semaglutide (Rybelsus) did not slow Alzheimer's disease progression in the highly awaited EVOKE phase III trials, Novo Nordisk announced Monday.

Read more at:

medpagetoday.comLink to medpagetoday.commedpagetoday.comNo photo description available.
← newer: Oral PCSK9 inhibitor enlicitide cut LDL 58% in familial hypeolder: Coffee is linked to lower risk of liver cirrhosis and liver →